Animal models to evaluate anti-atherosclerotic drugs

Fundamental and Clinical Pharmacology

Volumn 29, Issue 4, 2015, Pages 329-340

  Priyadharsini, Raman P ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Animal model; Apo E mice; Atherosclerosis

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CARDIOVASCULAR AGENT;

ANIMAL MODEL; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; DRUG EFFICACY; DRUG SCREENING; EXPERIMENTAL HAMSTER; EXPERIMENTAL MOUSE; EXPERIMENTAL RABBIT; EXPERIMENTAL RAT; FOAM CELL; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATORY CELL; MINIPIG; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; ANIMAL; CHEMICALLY INDUCED; DISEASE COURSE; DISEASE MODEL; GENETICS; HAMSTER; MOUSE; PATHOLOGY; PIG; RABBIT; RAT;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR AGENTS; CRICETINAE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; RABBITS; RATS; SWINE;

EID: 84935695207     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/fcp.12130     Document Type: Review

References (55)

1. Atherosclerosis and thrombosis: insights from large animal models [Internet]. Available from: http://www.hindawi.com/journals/bmri/2011/907575/ (accessed 15 April 2013).
2. Crowther M.A. Pathogenesis of atherosclerosis. ASH Educ. Program Book (2005) 1 436-441.
3. Alexander R.W. Hypertension and the pathogenesis of atherosclerosis oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension (1995) 25 155-161.
4. Fuster J.J., Castillo A.I., Zaragoza C., Ibáñez B., Andrés V. Animal models of atherosclerosis. Prog. Mol. Biol. Transl. Sci. (2012) 105 1-23.
5. Moghadasian M.H. Experimental atherosclerosis: a historical overview. Life Sci. (2002) 70 855-865.
6. Millon A., Canet-Soulas E., Boussel L., Fayad Z., Douek P. Animal models of atherosclerosis and magnetic resonance imaging for monitoring plaque progression. Vascular (2013) 14 1-17.
7. Singh V., Tiwari R.L., Dikshit M., Barthwal M.K. Models to study atherosclerosis: a mechanistic insight. Curr. Vasc. Pharmacol. (2009) 7 75-109.
8. Xiangdong L., Yuanwu L., Hua Z., Liming R., Qiuyan L., Ning L. Animal models for the atherosclerosis research: a review. Protein Cell. (2011) 2 189-201.
9. Vogel H.G. Drug discovery and evaluation: pharmacological assays; including a CD-ROM. Springer, New York, 2002, 1470 pp.
10. Russell J.C., Amy R.M., Manickavel V. et al. Prevention of myocardial disease in JCR: LA-corpulent rats by running. J. Appl. Physiol. Bethesda Md (1985) (1989) 66 1649-1655.
11. Getz G.S. Overview of murine atherosclerosis series. Curr. Drug Targets (2007) 8 1144-1149.
12. Potteaux S., Ait-Oufella H., Mallat Z. Mouse models of atherosclerosis. Drug Discov. Today Dis. Models (2007) 4 165-170.
13. Mukhopadhyay R. Mouse models of atherosclerosis: explaining critical roles of lipid metabolism and inflammation. J. Appl. Genet. (2013) 54 185-192.
14. Neuhofer A., Wernly B., Leitner L. et al. An accelerated mouse model for atherosclerosis and adipose tissue inflammation. Cardiovasc. Diabetol. (2014) 13 23.
15. Getz G.S., Reardon C.A. Animal models of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. (2012) 32 1104-1115.
16. Jensen T.W., Mazur M.J., Pettigew J.E., Perez-Mendoza V.G., Zachary J., Schook L.B. A cloned pig model for examining atherosclerosis induced by high fat, high cholesterol diets. Anim. Biotechnol. (2010) 21 179-187.
17. Davis B.T., Wang X.-J., Rohret J.A. et al. Targeted disruption of LDLR causes hypercholesterolemia and atherosclerosis in Yucatan miniature pigs. PLoS One (2014) 9 e93457.
18. Fernandez M.L., Volek J.S. Guinea pigs: a suitable animal model to study lipoprotein metabolism, atherosclerosis and inflammation. Nutr. Metab. (2006) 3 17.
19. Parmar N., Prakash S. Screening methods in pharmacology, Narosa, oxford, United kingdom, 2006.
20. Zwolak R.M., Kirkman T.R., Clowes A.W. Atherosclerosis in rabbit vein grafts. Arterioscler. Dallas Tex. (1989) 9 374-379.
21. Ishii A., Viñuela F., Murayama Y. et al. Swine model of carotid artery atherosclerosis: experimental induction by surgical partial ligation and dietary hypercholesterolemia. Am. J. Neuroradiol. (2006) 27 1893-1899.
22. Shi Z.-S., Feng L., He X. et al. Vulnerable plaque in a Swine model of carotid atherosclerosis. Am. J. Neuroradiol. (2009) 30 469-472.
23. Hayashi H., Niinobe S., Matsumoto Y., Suga T. Effects of Triton WR-1339 on lipoprotein lipolytic activity and lipid content of rat liver lysosomes. J. Biochem. (Tokyo). 1981 89 573-579.
24. Schurr P.E., Schultz J.R., Parkinson T.M. Triton-induced hyperlipidemia in rats as an animal model for screening hypolipidemic drugs. Lipids (1972) 7 68-74.
25. Otway S., Robinson D.S. The use of a non-ionic detergent (Triton WR 1339) to determine rates of triglyceride entry into the circulation of the rat under different physiological conditions. J. Physiol. (1967) 190 321-332.
26. Sui Y., Park S.-H., Helsley R.N. et al. Bisphenol A increases atherosclerosis in pregnane X receptor-humanized ApoE deficient mice. J. Am. Heart Assoc. (2014) 3 e000492.
27. Dumortier G., Grossiord J.L., Agnely F., Chaumeil J.C. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm. Res. (2006) 23 2709-2728.
28. Korolenko T.A., Tuzikov F.V., Johnston T.P. et al. The influence of repeated administration of poloxamer 407 on serum lipoproteins and protease activity in mouse liver and heart. Can. J. Physiol. Pharmacol. (2012) 90 1456-1468.
29. Jawień J., Nastałek P., Korbut R. Mouse models of experimental atherosclerosis. J. Physiol. Pharmacol. (2004) 55 503-517.
30. Daugherty A. Mouse models of atherosclerosis. Am. J. Med. Sci. (2002) 323 3-10.
31. Hewing B., Fisher E.A. Preclinical mouse models and methods for the discovery of the causes and treatments of atherosclerosis. Expert Opin. Drug Discov. (2012) 7 207-216.
32. Zadelaar S., Kleemann R., Verschuren L. et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler. Thromb. Vasc. Biol. (2007) 27 1706-1721.
33. Russell J.C. Of mice and men, rats and atherosclerosis. Cardiovasc. Res. (2003) 59 810-811.
34. Van Herck J.L., De Meyer G.R., Martinet W. et al. Impaired fibrillin-1 function promotes features of plaque instability in apolipoprotein E-deficient mice. Circulation (2009) 120 2478-2487.
35. Wu K.K., Huan Y. Diabetic atherosclerosis mouse models. Atherosclerosis (2007) 191 241-249.
36. Gonzalez-Navarro H., Burks D.J., Andres V. Murine models to investigate the influence of diabetic metabolism on the development of atherosclerosis and restenosis. Front Biosci. J. Virtual Libr. (2007) 12 4439-4455.
37. Mourad A.A., Heeba G.H., Taye A., El-Moselhy M.A. Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats. Fundam. Clin. Pharmacol. (2013) 27 489-497.
38. Weiss D., Kools J.J., Taylor W.R. Angiotensin II - induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation (2001) 103 448-454.
39. Abdel-Zaher A.O., Elkoussi A.E.A., Abudahab L.H., Elbakry M.H., Elsayed E.A-E. Effect of simvastatin on the antihypertensive activity of losartan in hypertensive hypercholesterolemic animals and patients: role of nitric oxide, oxidative stress, and high-sensitivity C-reactive protein. Fundam. Clin. Pharmacol. (2014) 28 237-248.
40. Cullen P., Baetta R., Bellosta S. et al. Rupture of the atherosclerotic plaque does a good animal model exist? Arterioscler. Thromb. Vasc. Biol. (2003) 23 535-542.
41. Rekhter M.D. How to evaluate plaque vulnerability in animal models of atherosclerosis? Cardiovasc. Res. (2002) 54 36-41.
42. Rekhter M. Vulnerable atherosclerotic plaque: emerging challenge for animal models. Curr. Opin. Cardiol. (2002) 17 626-632.
43. Rosenfeld M.E., Carson K.G.S., Johnson J.L., Williams H., Jackson C.L., Schwartz S.M. Animal models of spontaneous plaque rupture: the holy grail of experimental atherosclerosis research. Curr. Atheroscler. Rep. (2002) 4 238-242.
44. Sun X., Cao W., Cui J. et al. An animal model of atherosclerotic plaque disruption and thrombosis in rabbit using pharmacological triggering to plaques induced by perivascular collar placement. Cardiovasc. Pathol. (2013) 22 264-269.
45. Shiomi M., Ito T., Yamada S., Kawashima S., Fan J. Correlation of vulnerable coronary plaques to sudden cardiac events. Lessons from a myocardial infarction-prone animal model (the WHHLMI rabbit). J. Atheroscler. Thromb. (2003) 11 184-189.
46. Phinikaridou A., Hallock K.J., Qiao Y., Hamilton J.A. A robust rabbit model of human atherosclerosis and atherothrombosis. J. Lipid Res. (2009) 50 787-797.
47. Fang S.-M., Zhang Q.-H., Jiang Z.-X. Developing a novel rabbit model of atherosclerotic plaque rupture and thrombosis by cold-induced endothelial injury. J. Biomed. Sci. (2009) 16 39.
48. Bjoerklund M.M., Hollensen A.K., Hagensen M.K. et al. Induction of atherosclerosis in mice and hamsters without germline genetic engineering. Circ. Res. (2014) 114 1684-1689.
49. Chen H., Wu T., Kerwin W.S., Yuan C. Atherosclerotic plaque inflammation quantification using dynamic contrast-enhanced (DCE) MRI. Quant. Imaging Med. Surg. (2013) 3 298-301.
50. Corti R., Fuster V. Imaging of atherosclerosis: magnetic resonance imaging. Eur. Heart J. (2011) 32 1709-1719b.
51. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. (2005) 19 117-125.
52. Shao L., Zhang Y., Ma A. et al. Atorvastatin preconditioning improves the forward blood flow in the no-reflow rats. Fundam. Clin. Pharmacol. (2014) 28 42-52.
53. Endo A. A historical perspective on the discovery of statins. Proc. Jpn Acad. Ser B Phys. Biol. Sci. (2010) 86 484-493.
54. Hopkins P.N. Molecular biology of atherosclerosis. Physiol. Rev. (2013) 93 1317-1542.
55. Jamkhande P.G., Chandak P.G., Dhawale S.C., Barde S.R., Tidke P.S., Sakhare R.S. Therapeutic approaches to drug targets in atherosclerosis. Saudi Pharm. J. (2014) 22 179-190.